Floatz logo

DL-DOBUTAMINE

Asthma

Wake Forest University Health SciencesSmall moleculeEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Asthma cohort.

Asset / SponsorPhaseRating
Budesonide
New York City Health and Hospitals Corporation
Phase 4BBB
SALMETEROL
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 4BBB
Flixotide
GlaxoSmithKline
Phase 4BBB
Montelukast
Kafrelsheikh University
Phase 4BBB
MK-0476
Organon and Co
Phase 4BB

View all 48 →

Same molecule, other indications

DL-DOBUTAMINE is also rated in:

traumatic brain injuryDormant
CCC
Indicative ·
53 / 100
View asset →
infectious disease with sepsisDormant
CCC
Indicative ·
53 / 100
View asset →
vascular insufficiency disorderDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →